Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Share this:

Dec 18, 2014 · Leave a Reply

Vedolizumab Is Better for Ulcerative Colitis Than Crohn's Disease

By Margaret Shepard, Communications Associate @Margaret_Marie

In December 2013, two Food and Drug Administration (FDA) advisory committees voted in favor of recommending vedolizumab for treatment of both types of inflammatory bowel disease.

A theoretical concern about vedolizumab is the risk of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection associated with vedolizumab's parent molecule, natalizumab (Tysabri), which is approved for use in both multiple sclerosis and CD.

Edward V. Loftus Jr., M.D., a gastroenterologist at Mayo Clinic in Minnesota, points out that natalizumab affects adhesion molecules at the level of the blood-brain barrier system as well as in the gut. "The goal has always been to develop more gut-specific targets," he says.

Read more about vedolizumab in the Digestive Diseases update.

To learn more about IBD, visit mayoclinic.org/ibd.

Tags: clinical trials, Crohn's disease, Edward Loftus, IBD, News Alerts, ulcerative colitis, Vedolizumab

Please login or become a member to post a comment.

Contact Us · Privacy Policy